300138.SZ
晨光生物
SZSE · Consumer Defensive · C 制造业 · CN
CNY 10.96
−0.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.5B | 6.6B | 7.0B | 6.9B | 6.3B |
| Cost of Revenue | 5.6B | 5.7B | 6.4B | 6.1B | 5.4B |
| Gross Profit | 839.2M | 859.3M | 556.9M | 797.9M | 877.7M |
| Operating Expenses | |||||
| R&D Expense | 157.8M | 166.2M | 128.6M | 97.4M | 129.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 162.2M | 170.8M | 160.6M | 154.6M | 192.9M |
| Selling & Marketing Expense | 61.9M | 59.8M | 50.1M | 61.1M | 59.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 462.6M | 479.0M | 430.7M | 377.2M | 420.4M |
| Cost and Expenses | 6.1B | 6.2B | 6.9B | 6.5B | 5.8B |
| Operating Income (EBIT) | 420.2M | 436.4M | 106.0M | 548.3M | 487.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 420.5M | 437.9M | 106.9M | 555.8M | 501.8M |
| Income Tax Expense | 58.4M | 63.0M | 29.0M | 61.6M | 65.7M |
| Bottom Line | |||||
| Net Income | 356.1M | 368.9M | 94.0M | 479.7M | 434.0M |
| Earnings from Cont. Ops | 362.1M | 374.9M | 78.0M | 494.2M | 436.1M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 356.1M | 368.9M | 94.0M | 479.7M | 434.0M |
| Per Share | |||||
| Basic EPS | CN¥0.74 | CN¥0.76 | CN¥0.18 | CN¥0.90 | CN¥0.81 |
| Diluted EPS | CN¥0.74 | CN¥0.76 | CN¥0.18 | CN¥0.90 | CN¥0.81 |
| Revenue Per Share | CN¥13.40 | CN¥13.58 | CN¥13.52 | CN¥12.92 | CN¥11.82 |
| Shares | |||||
| Basic Shares Outstanding | 483.1M | 483.1M | 517.3M | 532.0M | 532.8M |
| Diluted Shares Outstanding | 483.1M | 483.1M | 517.3M | 532.0M | 532.8M |
| Profitability Metrics | |||||
| EBITDA | — | 619.9M | 272.9M | 701.1M | 632.2M |
| D&A | — | 183.6M | 166.9M | 152.7M | 145.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026